ArticleJournal for immunotherapy of cancer2024

Inhibition of IL-25/IL-17RA improves immune-related adverse events of checkpoint inhibitors and reveals antitumor activity.

Xizi Hu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.